摘要
心脑血管疾病是人类的死因之首,动脉粥样硬化(atherosclerosis,As)是其发生的病理基础。他汀类药物有明确的降血脂功效,可改善As,但其对某些高脂血症患者无效,长期使用可引发严重不良反应。烟酸(niacin,NA)可通过激动其受体GPR109A,产生独特降脂、抗炎、保护内皮作用,与他汀类联用,可明显改善As。该文从烟酸抗As作用、烟酸受体、新型受体激动剂、与他汀类联合用药四个方面,综述了烟酸与烟酸受体研究进展,以期为基于烟酸受体激动剂的抗As药物研发提供新思路。
Cardiovascular and cerebrovascular diseases are the leading cause of death among human worldwide,and atherosclerosis(As)is the key pathological basis.Statins can reduce blood lipid and inhibit As.However,they make no difference in some patients with hyperlipidemia and may lead to serious adverse reactions in large doses.Nicotinic acid(NA)can result in special lipid-lowering,anti-inflammatory effect and protect vascular endothelium by exciting NA receptor GPR109A.Additionally,NA combined with Statins can make a marked inhibition in As.This review summarizes the research progress on NA and NA receptor agonists from four aspects including anti-atherosclerosis,NA receptor,new NA receptor agonists and NA combination with statins,aiming to provide new ideas for anti-atherosclerosis drug development based on NA receptor agonists.
作者
李慧瑾
金曦
李鹏权
尹凡
弓雪
曹慧玲
LI Hui-jin;Jin Xi;LI Peng-quan;YIN Fan;GONG Xue;CAO Hui-ling(Shaanxi Key Lab of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University,Xi'an 710021, China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2020年第10期1341-1345,共5页
Chinese Pharmacological Bulletin
基金
陕西省教育厅2018年度重点科学研究计划(No 18JS103)。
